Literature DB >> 18775367

Pharmacotherapy of irritability in pervasive developmental disorders.

Kimberly A Stigler1, Christopher J McDougle.   

Abstract

Children and adolescents diagnosed with autism and related pervasive developmental disorders (PDDs) often sustain irritability, including aggression, self-injurious behavior, and tantrums. Research to date supports the use of the atypical antipsychotics as a first-line pharmacologic treatment for this target symptom domain in PDDs. Currently, the atypical antipsychotic risperidone is the only medication approved by the US Food and Drug Administration for irritability in youth with autism. Additional large-scale, placebo-controlled studies of other medications are needed to determine their efficacy for the treatment of irritability in this diagnostic group.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18775367     DOI： 10.1016/j.chc.2008.06.002

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN： 1056-4993


  11 in total

1.  Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder.

Authors:  Jessica F Douglas; Kevin B Sanders; M Hannah Benneyworth; Jessica L Smith; Virginia M Dejean; Susan G McGrew; Jeremy Veenstra-Vanderweele
Journal:  J Autism Dev Disord       Date:  2013-05

2.  Symptoms of autism and schizophrenia spectrum disorders in clinically referred youth with oppositional defiant disorder.

Authors:  Kenneth D Gadow; Deborah A G Drabick
Journal:  Res Dev Disabil       Date:  2012-03-22

Review 3.  Issues in the management of challenging behaviours of adults with autism spectrum disorder.

Authors:  Johnny L Matson; Megan Sipes; Jill C Fodstad; Mary E Fitzgerald
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

4.  Paliperidone for irritability in adolescents and young adults with autistic disorder.

Authors:  Kimberly A Stigler; Jennifer E Mullett; Craig A Erickson; David J Posey; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2012-05-03       Impact factor: 4.530

5.  Reduction of Aggressive Episodes After Repeated Transdermal Nicotine Administration in a Hospitalized Adolescent with Autism Spectrum Disorder.

Authors:  Gerrit I Van Schalkwyk; Alan S Lewis; Zheala Qayyum; Kourtney Koslosky; Marina R Picciotto; Fred R Volkmar
Journal:  J Autism Dev Disord       Date:  2015-09

Review 6.  Autoimmunity in autism.

Authors:  Amanda M Enstrom; Judy A Van de Water; Paul Ashwood
Journal:  Curr Opin Investig Drugs       Date:  2009-05

Review 7.  Emerging role of aripiprazole for treatment of irritability associated with autistic disorder in children and adolescents.

Authors:  Joan Stachnik; Michael Gabay
Journal:  Adolesc Health Med Ther       Date:  2010-09-15

Review 8.  Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children.

Authors:  Eiji Kirino
Journal:  Clin Med Insights Pediatr       Date:  2014-05-25

Review 9.  Aggression in autism spectrum disorder: presentation and treatment options.

Authors:  Sarah E Fitzpatrick; Laura Srivorakiat; Logan K Wink; Ernest V Pedapati; Craig A Erickson
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-23       Impact factor: 2.570

10.  Octopamine neuron dependent aggression requires dVGLUT from dual-transmitting neurons.

Authors:  Lewis M Sherer; Elizabeth Catudio Garrett; Hannah R Morgan; Edmond D Brewer; Lucy A Sirrs; Harold K Shearin; Jessica L Williams; Brian D McCabe; R Steven Stowers; Sarah J Certel
Journal:  PLoS Genet       Date:  2020-02-25       Impact factor: 5.917
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.